Skip to main content
SpringerLink
Log in

Pathology and molecular genetics of oligodendroglial tumors

  • Guest Editor Review
  • Published:
Journal of Molecular Medicine Aims and scope Submit manuscript

Abstract

Oligodendroglial gliomas are second only to astrocytic gliomas in frequency. The lack of stringent diagnostic criteria cause high interobserver variation in regard to classification and grading of these tumors. Previous studies have described oligodendrogliomas with features that overlap with those of neurocytic tumors, thus further complicating diagnostic decisions. The increasing need for standardized diagnostic criteria in this subset of gliomas is emphasized by the benefit of adjuvant therapies in patients with anaplastic oligodendrogliomas. Characteristic chromosomal aberrations have been successfully determined for oligodendroglial tumors in recent years. In contrast to astrocytomas, however, no genes in the affected regions have been clearly linked to their pathogenesis. However, the molecular findings promise to be helpful for diagnostic and therapeutic decisions. This review compiles clinical, pathological, and molecular genetic findings on WHO grades II and III oligodendrogliomas and oligoastrocytomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

GFAP :

Glial fibrillary acid protein

LOH :

Loss of heterozygosity

O2A :

Oligodendrocyte type 2 astrocyte progenitor

PCV :

Procarbazine, CCNU, vincristine regimen

PDGFR :

Platelet-derived growth factor receptor

TGF :

Transforming growth factor

EGFR :

Epithelial growth factor

References

  1. Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system, 2nd edn. IARC, Lyon

  2. Bailey P, Cushing H (1926) A classification of tumors of the glioma group on a histogenetic basis with a correlation study of prognosis. Lippincott, Philadelphia

  3. Bailey P, Bucy P (1929) Oligodendrogliomas of the brain. J Pathol Bacteriol 32:735–754

    Google Scholar 

  4. Smith MT, Ludwig CL, Godfrey AD, Armbrustmacher VW (1983) Grading of oligodendrogliomas. Cancer 52:2107–2114

    CAS  PubMed  Google Scholar 

  5. Kros JM, Troost D, van Eden CG, van der Werf AJ, Uylings HB (1988) Oligodendroglioma. A comparison of two grading systems. Cancer 61:2251–2259

    CAS  PubMed  Google Scholar 

  6. Shaw EG, Scheithauer BW, O’Fallon JR, Tazelaar HD, Davis DH (1992) Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76:428–434

    CAS  PubMed  Google Scholar 

  7. Mork SJ, Lindegaard KF, Halvorsen TB, Lehmann EH, Solgaard T, Hatlevoll R, Harvei S, Ganz J (1985) Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 63:881–889

    CAS  PubMed  Google Scholar 

  8. Helseth A, Mork SJ (1989) Neoplasms of the central nervous system in Norway. III. Epidemiological characteristics of intracranial gliomas according to histology. APMIS 97:547–555

    CAS  PubMed  Google Scholar 

  9. Zulch K (1986) Brain tumours. Their biology and pathology, 3rd edn. Springer, Berlin Heidelberg New York

  10. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381–1393

    Article  CAS  PubMed  Google Scholar 

  11. Ironside JW, Moss TH, Louis DN, Lowe JS, Well RO (2002) Diagnostic pathology of nervous system tumours. Churchill Livingstone, London

  12. Winger MJ, Macdonald DR, Cairncross JG (1989) Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 71:487–493

    CAS  PubMed  Google Scholar 

  13. Nijjar TS, Simpson WJ, Gadalla T, McCartney M (1993) Oligodendroglioma. The Princess Margaret Hospital experience (1958–1984). Cancer 71:4002–4006

    CAS  PubMed  Google Scholar 

  14. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A (1994) Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 35:1018–1034–

    CAS  PubMed  Google Scholar 

  15. Ludwig CL, Smith MT, Godfrey AD, Armbrustmacher VW (1986) A clinicopathological study of 323 patients with oligodendrogliomas. Ann Neurol 19:15–21

    CAS  PubMed  Google Scholar 

  16. Jaskolsky D, Zawirski M, Papierz W, Kotwica Z (1987) Mixed gliomas. Their clinical course and results of surgery. Zentralbl Neurochir 48:120–123

    CAS  PubMed  Google Scholar 

  17. Huang CI, Chiou WH, Ho DM (1987) Oligodendroglioma occurring after radiation therapy for pituitary adenoma. J Neurol Neurosurg Psychiatry 50:1619–1624

    CAS  PubMed  Google Scholar 

  18. Perez-Diaz C, Cabello A, Lobato RD, Rivas JJ, Cabrera A (1985) Oligodendrogliomas arising in the scar of a brain contusion. Report of two surgically verified cases. Surg Neurol 24:581–586

    Article  CAS  PubMed  Google Scholar 

  19. Giordana MT, Mauro A, Soffietti R, Leone M (1981) Association between multiple sclerosis and oligodendroglioma. Case report. Ital J Neurol Sci 2:403–409

    CAS  PubMed  Google Scholar 

  20. Kros JM, Lie ST, Stefanko SZ (1994) Familial occurrence of polymorphous oligodendroglioma. Neurosurgery 34:732–736

    CAS  PubMed  Google Scholar 

  21. Ferraresi S, Servello D, De Lorenzi L, Allegranza A (1989) Familial frontal lobe oligodendroglioma. Case report. J Neurosurg Sci 33:317–318

    CAS  PubMed  Google Scholar 

  22. Herbarth B, Meissner H, Westphal M, Wegner M (1998) Absence of polyomavirus JC in glial brain tumors and glioma-derived cell lines. Glia 22:415–420

    Article  CAS  PubMed  Google Scholar 

  23. Huang H, Reis R, Yonekawa Y, Lopes JM, Kleihues P, Ohgaki H (1999) Identification in human brain tumors of DNA sequences specific for SV40 large T antigen. Brain Pathol 9:33–42

    CAS  PubMed  Google Scholar 

  24. Druckrey H, Ivankovic S, Preussmann R, Landschutz C, Stekar J, Brunner U, Schagen B (1968) Transplacentar induction of neurogenic malignomas by 1:2-diethyl-hydrazine, azo-, and azoxy-ethane in rats. Experientia 24:561–562

    CAS  PubMed  Google Scholar 

  25. Graham DI, Lantos PL (1997) Greenfield’s neuropathology, 6th edn. Arnold, London

  26. Tice H, Barnes PD, Goumnerova L, Scott RM, Tarbell NJ (1993) Pediatric and adolescent oligodendrogliomas. AJNR Am J Neuroradiol 14:1293–1300

    CAS  PubMed  Google Scholar 

  27. Lee YY, Van Tassel P (1989) Intracranial oligodendrogliomas: imaging findings in 35 untreated cases. AJR Am J Roentgenol 152:361–369

    CAS  PubMed  Google Scholar 

  28. Chin HW, Hazel JJ, Kim TH, Webster JH (1980) Oligodendrogliomas. I. A clinical study of cerebral oligodendrogliomas. Cancer 45:1458–466

    CAS  PubMed  Google Scholar 

  29. Hart MN, Petito CK, Earle KM (1974) Mixed gliomas. Cancer 33:134–140

    CAS  PubMed  Google Scholar 

  30. Kim L, Hochberg FH, Thornton AF, Harsh GRt, Patel H, Finkelstein D, Louis DN (1996) Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 85:602–607

    CAS  PubMed  Google Scholar 

  31. Mork SJ, Halvorsen TB, Lindegaard KF, Eide GE (1986) Oligodendroglioma. Histologic evaluation and prognosis. J Neuropathol Exp Neurol 45:65–78

    CAS  PubMed  Google Scholar 

  32. Tanaka J, Hokama Y, Nakamura H (1988) Myelin basic protein as a possible marker for oligodendroglioma. Acta Pathol Jpn 38:1297–303

    CAS  PubMed  Google Scholar 

  33. Kashima T, Tiu SN, Merrill JE, Vinters HV, Dawson G, Campagnoni AT (1993) Expression of oligodendrocyte-associated genes in cell lines derived from human gliomas and neuroblastomas. Cancer Res 53:170–175

    CAS  PubMed  Google Scholar 

  34. Monte SM de la (1989) Uniform lineage of oligodendrogliomas. Am J Pathol 135:529–540

    PubMed  Google Scholar 

  35. Kennedy PG, Watkins BA, Thomas DG, Noble MD (1987) Antigenic expression by cells derived from human gliomas does not correlate with morphological classification. Neuropathol Appl Neurobiol 13:327–347

    CAS  PubMed  Google Scholar 

  36. Perentes E, Rubinstein LJ (1987) Recent applications of immunoperoxidase histochemistry in human neuro-oncology. An update. Arch Pathol Lab Med 111:796–812

    CAS  PubMed  Google Scholar 

  37. Lu QR, Park JK, Noll E, Chan JA, Alberta J, Yuk D, Alzamora MG, Louis DN, Stiles CD, Rowitch DH, Black PM (2001) Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci U S A 98:10851–1086

    Article  CAS  PubMed  Google Scholar 

  38. Marie Y, Sanson M, Mokhtari K, Leuraud P, Kujas M, Delattre JY, Poirier J, Zalc B, Hoang-Xuan K (2001) OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 358:298–300

    Article  CAS  PubMed  Google Scholar 

  39. Ohnishi A, Sawa H, Tsuda M, Sawamura Y, Itoh T, Iwasaki Y, Nagashima K (2003) Expression of the oligodendroglial lineage-associated markers Olig1 and Olig2 in different types of human gliomas. J Neuropathol Exp Neurol 62:1052–1059

    CAS  PubMed  Google Scholar 

  40. Landry CF, Verity MA, Cherman L, Kashima T, Black K, Yates A, Campagnoni AT (1997) Expression of oligodendrocytic mRNAs in glial tumors: changes associated with tumor grade and extent of neoplastic infiltration. Cancer Res 57:4098–4104

    CAS  PubMed  Google Scholar 

  41. Shoshan Y, Nishiyama A, Chang A, Mork S, Barnett GH, Cowell JK, Trapp BD, Staugaitis SM (1999) Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci U S A 96:10361–10366

    Article  CAS  PubMed  Google Scholar 

  42. Whitton AC, Bloom HJ (1990) Low grade glioma of the cerebral hemispheres in adults: a retrospective analysis of 88 cases. Int J Radiat Oncol Biol Phys 18:783–786

    CAS  PubMed  Google Scholar 

  43. Puduvalli VK, Hashmi M, McAllister LD, Levin VA, Hess KR, Prados M, Jaeckle KA, Yung WK, Buys SS, Bruner JM, Townsend JJ, Davis R, Sawaya R, Kyritsis AP (2003) Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology 65:259–266

    Google Scholar 

  44. Lindegaard KF, Mork SJ, Eide GE, Halvorsen TB, Hatlevoll R, Solgaard T, Dahl O, Ganz J (1987) Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg 67:224–230

    CAS  PubMed  Google Scholar 

  45. Sun ZM, Genka S, Shitara N, Akanuma A, Takakura K (1988) Factors possibly influencing the prognosis of oligodendroglioma. Neurosurgery 22:886–891

    CAS  PubMed  Google Scholar 

  46. Fortin D, Macdonald DR, Stitt L, Cairncross JG (2001) PCV for oligodendroglial tumors: in search of prognostic factors for response and survival. Can J Neurol Sci 28:215–223

    CAS  PubMed  Google Scholar 

  47. Cairncross JG, Macdonald DR (1988) Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23:360–364

    CAS  PubMed  Google Scholar 

  48. Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, Wilson CB (1980) Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64:237–244

    CAS  PubMed  Google Scholar 

  49. Kyritsis AP, Yung WK, Bruner J, Gleason MJ, Levin VA (1993) The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 32:365–370

    CAS  PubMed  Google Scholar 

  50. Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D, Rattner B (1992) The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 76:741–745

    CAS  PubMed  Google Scholar 

  51. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr et al. (1994) Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:2013–2021

    CAS  PubMed  Google Scholar 

  52. Fortin D, Cairncross GJ, Hammond RR (1999) Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 45:1279–1291

    CAS  PubMed  Google Scholar 

  53. Bent MJ van den, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CC, Vecht CJ, Allgeier A, Gorlia T (2003) Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21:2525–2528

    Article  PubMed  Google Scholar 

  54. Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, Sardell S, Traish D, Gonsalves A, Wilkins P, Westbury C (2003) Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14:1715–1721

    Article  CAS  PubMed  Google Scholar 

  55. Chahlavi A, Kanner A, Peereboom D, Staugaitis SM, Elson P, Barnett G (2003) Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol 61:267–273

    Article  PubMed  Google Scholar 

  56. Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncross JG (1996) Salvage chemotherapy for oligodendroglioma. J Neurosurg 85:597–601

    CAS  PubMed  Google Scholar 

  57. Engelhard HH, Stelea A, Mundt A (2003) Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 60:443–456

    Article  PubMed  Google Scholar 

  58. Henderson KH, Shaw EG (2001) Randomized trials of radiation therapy in adult low-grade gliomas. Semin Radiat Oncol 11:145–151

    Article  CAS  PubMed  Google Scholar 

  59. Wallner KE, Gonzales M, Sheline GE (1988) Treatment of oligodendrogliomas with or without postoperative irradiation. J Neurosurg 68:684–688

    CAS  PubMed  Google Scholar 

  60. Sheline GE (1977) Radiation therapy of brain tumors. Cancer 39:873–881

    CAS  PubMed  Google Scholar 

  61. Allison RR, Schulsinger A, Vongtama V, Barry T, Shin KH (1997) Radiation and chemotherapy improve outcome in oligodendroglioma. Int J Radiat Oncol Biol Phys 37:399–403

    Article  CAS  PubMed  Google Scholar 

  62. Macdonald DR (1994) Low-grade gliomas, mixed gliomas, and oligodendrogliomas. Semin Oncol 21:236–248

    CAS  PubMed  Google Scholar 

  63. Leonardi MA, Lumenta CB (2001) Oligodendrogliomas in the CT/MR-era. Acta Neurochir (Wien) 143:1195–1203

    Google Scholar 

  64. Jeremic B, Shibamoto Y, Gruijicic D, Milicic B, Stojanovic M, Nikolic N, Dagovic A, Aleksandrovic J (1999) Combined treatment modality for anaplastic oligodendroglioma: a phase II study. J Neurooncol 43:179–185

    Article  CAS  PubMed  Google Scholar 

  65. Bullard DE, Rawlings CE, 3rd, Phillips B, Cox EB, Schold SC Jr, Burger P, Halperin EC (1987) Oligodendroglioma. An analysis of the value of radiation therapy. Cancer 60:2179–2188

    CAS  PubMed  Google Scholar 

  66. Dehghani F, Schachenmayr W, Laun A, Korf HW (1998) Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol (Berl) 95:493–504

    Google Scholar 

  67. Kirby S, Macdonald D, Fisher B, Gaspar L, Cairncross G (1996) Pre-radiation chemotherapy for malignant glioma in adults. Can J Neurol Sci 23:123–127

    CAS  PubMed  Google Scholar 

  68. Kros JM, Pieterman H, van Eden CG, Avezaat CJ (1994) Oligodendroglioma: the Rotterdam-Dijkzigt experience. Neurosurgery 34:959–966

    CAS  PubMed  Google Scholar 

  69. Reedy DP, Bay JW, Hahn JF (1983) Role of radiation therapy in the treatment of cerebral oligodendroglioma: an analysis of 57 cases and a literature review. Neurosurgery 13:499–503

    CAS  PubMed  Google Scholar 

  70. Westergaard L, Gjerris F, Klinken L (1997) Prognostic factors in oligodendrogliomas. Acta Neurochir (Wien) 139:600–605

    Google Scholar 

  71. Yeh SA, Lee TC, Chen HJ, Lui CC, Sun LM, Wang CJ, Huang EY (2002) Treatment outcomes and prognostic factors of patients with supratentorial low-grade oligodendroglioma. Int J Radiat Oncol Biol Phys 54:1405–1409

    Article  PubMed  Google Scholar 

  72. Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS (1994) The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 30:567–573

    CAS  PubMed  Google Scholar 

  73. Walker DG, Kaye AH (2001) Diagnosis and management of astrocytomas, oligodendrogliomas and mixed gliomas: a review. Australas Radiol 45:472–482

    Article  CAS  PubMed  Google Scholar 

  74. Perry JR, Brown MT, Gockerman JP (1998) Acute leukemia following treatment of malignant glioma. J Neurooncol 40:39–46

    Article  CAS  PubMed  Google Scholar 

  75. Heegaard S, Sommer HM, Broholm H, Broendstrup O (1995) Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 76:1809–1813

    CAS  PubMed  Google Scholar 

  76. Olson JD, Riedel E, DeAngelis LM (2000) Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54:1442–1448

    CAS  PubMed  Google Scholar 

  77. Wharton SB, Hamilton FA, Chan WK, Chan KK, Anderson JR (1998) Proliferation and cell death in oligodendrogliomas. Neuropathol Appl Neurobiol 24:21–28

    Article  CAS  PubMed  Google Scholar 

  78. Shimizu KT, Tran LM, Mark RJ, Selch MT (1993) Management of oligodendrogliomas. Radiology 186:569–572

    CAS  PubMed  Google Scholar 

  79. Bent MJvan den , Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W (1998) Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 51:1140–1145

    PubMed  Google Scholar 

  80. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479

    Article  CAS  PubMed  Google Scholar 

  81. Davis FG, Freels S, Grutsch J, Barlas S, Brem S (1998) Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J Neurosurg 88:1–10

    CAS  PubMed  Google Scholar 

  82. Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645

    CAS  PubMed  Google Scholar 

  83. Sasaki H, Zlatescu MC, Betensky RA, Johnk LB, Cutone AN, Cairncross JG, Louis DN (2002) Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade “oligodendroglioma.” J Neuropathol Exp Neurol 61:58–63

    Google Scholar 

  84. Buckner JC, Gesme D Jr, O’Fallon JR, Hammack JE, Stafford S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG, Jenkins R (2003) Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 21:251–255

    Article  PubMed  Google Scholar 

  85. Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, Stitt L, Louis DN, Cairncross JG (2000) Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 48:825–830

    Article  CAS  PubMed  Google Scholar 

  86. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN (2001) Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 7:839–845

    CAS  PubMed  Google Scholar 

  87. Hashimoto N, Murakami M, Takahashi Y, Fujimoto M, Inazawa J, Mineura K (2003) Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p. Cancer 97:2254–2261

    Article  CAS  PubMed  Google Scholar 

  88. Thiessen B, Maguire JA, McNeil K, Huntsman D, Martin MA, Horsman D (2003) Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol 64:271–278

    Article  PubMed  Google Scholar 

  89. Bent MJ van den , Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM (2003) Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97:1276–1284

    Article  PubMed  Google Scholar 

  90. Hoang-Xuan K, He J, Huguet S, Mokhtari K, Marie Y, Kujas M, Leuraud P, Capelle L, Delattre JY, Poirier J, Broet P, Sanson M (2001) Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 57:1278–1281

    CAS  PubMed  Google Scholar 

  91. Sanson M, Leuraud P, Aguirre-Cruz L, He J, Marie Y, Cartalat-Carel S, Mokhtari K, Duffau H, Delattre JY, Hoang-Xuan K (2002) Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas. J Neurosurg 97:1397–1401

    CAS  PubMed  Google Scholar 

  92. Deimling A von, Kleihues P, Saremaslani P, Yasargil MG, Spoerri O, Sudhof TC, Wiestler OD (1991) Histogenesis and differentiation potential of central neurocytomas. Lab Invest 64:585–591

    PubMed  Google Scholar 

  93. Deimling A von, Janzer R, Kleihues P, Wiestler OD (1990) Patterns of differentiation in central neurocytoma. An immunohistochemical study of eleven biopsies. Acta Neuropathol (Berl) 79:473–479

    Google Scholar 

  94. Raff MC, Miller RH, Noble M (1983) A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature 303:390–396

    CAS  PubMed  Google Scholar 

  95. Scolding NJ, Rayner PJ, Sussman J, Shaw C, Compston DA (1995) A proliferative adult human oligodendrocyte progenitor. Neuroreport 6:441–445

    CAS  PubMed  Google Scholar 

  96. Noble M, Wren D, Wolswijk G (1992) The O-2A (adult) progenitor cell: a glial stem cell of the adult central nervous system. Semin Cell Biol 3:413–422

    CAS  PubMed  Google Scholar 

  97. Levine JM, Stincone F, Lee YS (1993) Development and differentiation of glial precursor cells in the rat cerebellum. Glia 7:307–721

    CAS  PubMed  Google Scholar 

  98. Armstrong RC, Dorn HH, Kufta CV, Friedman E, Dubois-Dalcq ME (1992) Pre-oligodendrocytes from adult human CNS. J Neurosci 12:1538–1547

    CAS  PubMed  Google Scholar 

  99. Prabhakar S, D’Souza S, Antel JP, McLaurin J, Schipper HM, Wang E (1995) Phenotypic and cell cycle properties of human oligodendrocytes in vitro. Brain Res 672:159–169

    Article  CAS  PubMed  Google Scholar 

  100. Scolding NJ, Rayner PJ, Compston DA (1999) Identification of A2B5-positive putative oligodendrocyte progenitor cells and A2B5-positive astrocytes in adult human white matter. Neuroscience 89:1–4

    Article  CAS  PubMed  Google Scholar 

  101. Milner R, Ffrench-Constant C (1994) A developmental analysis of oligodendroglial integrins in primary cells: changes in alpha v-associated beta subunits during differentiation. Development 120:3497–3506

    CAS  PubMed  Google Scholar 

  102. Kettenmann H, Blankenfeld GV, Trotter J (1991) Physiological properties of oligodendrocytes during development. Ann N Y Acad Sci 633:64–77

    CAS  PubMed  Google Scholar 

  103. Blankenfeld G Von, Ransom BR, Kettenmann H (1993) Development of cell-cell coupling among cells of the oligodendrocyte lineage. Glia 7:322–328

    PubMed  Google Scholar 

  104. Pringle NP, Richardson WD (1993) A singularity of PDGF alpha-receptor expression in the dorsoventral axis of the neural tube may define the origin of the oligodendrocyte lineage. Development 117:525–533

    CAS  PubMed  Google Scholar 

  105. Bansal R, Pfeiffer SE (1994) Inhibition of protein and lipid sulfation in oligodendrocytes blocks biological responses to FGF-2 and retards cytoarchitectural maturation, but not developmental lineage progression. Dev Biol 162:511–524

    Article  CAS  PubMed  Google Scholar 

  106. Ishii S, Volpe JJ (1992) Glycoprotein processing is required for completion but not initiation of oligodendroglial differentiation from its bipotential progenitor cell. Dev Neurosci 14:221–229

    CAS  PubMed  Google Scholar 

  107. Bishop M, de la Monte SM (1989) Dual lineage of astrocytomas. Am J Pathol 135:517–527

    CAS  PubMed  Google Scholar 

  108. Nishiyama A, Lin XH, Giese N, Heldin CH, Stallcup WB (1996) Co-localization of NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells in the developing rat brain. J Neurosci Res 43:299–314

    Article  CAS  PubMed  Google Scholar 

  109. Nishiyama A, Yu M, Drazba JA, Tuohy VK (1997) Normal and reactive NG2+ glial cells are distinct from resting and activated microglia. J Neurosci Res 48:299–312

    Article  CAS  PubMed  Google Scholar 

  110. Reynolds R, Hardy R (1997) Oligodendroglial progenitors labeled with the O4 antibody persist in the adult rat cerebral cortex in vivo. J Neurosci Res 47:455–470

    Article  CAS  PubMed  Google Scholar 

  111. Trapp BD, Nishiyama A, Cheng D, Macklin W (1997) Differentiation and death of premyelinating oligodendrocytes in developing rodent brain. J Cell Biol 137:459–468

    Article  CAS  PubMed  Google Scholar 

  112. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15:1913–1925

    Article  CAS  PubMed  Google Scholar 

  113. Holland EC, Li Y, Celestino J, Dai C, Schaefer L, Sawaya RA, Fuller GN (2000) Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo. Am J Pathol 157:1031–1037

    CAS  PubMed  Google Scholar 

  114. Weiss WA, Burns MJ, Hackett C, Aldape K, Hill JR, Kuriyama H, Kuriyama N, Milshteyn N, Roberts T, Wendland MF, DePinho R, Israel MA (2003) Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 63:1589–1595

    CAS  PubMed  Google Scholar 

  115. Bello MJ, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Saez-Castresana J, Pestana A, Rey JA (1994) Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer 57:172–175

    CAS  PubMed  Google Scholar 

  116. Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Pestana A, Rey JA (1995) Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 64:207–210

    CAS  PubMed  Google Scholar 

  117. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestler OD, von Deimling A (1995) Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54:91–95

    CAS  PubMed  Google Scholar 

  118. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175–1190

    CAS  PubMed  Google Scholar 

  119. von Deimling A, Louis DN, von Ammon K, Petersen I, Wiestler OD, Seizinger BR (1992) Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 52:4277–4279

    PubMed  Google Scholar 

  120. Reifenberger G, Louis DN (2003) Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62:111–126

    CAS  PubMed  Google Scholar 

  121. Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, Cairncross JG (2001) Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61:6713–6715

    CAS  PubMed  Google Scholar 

  122. Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller M, Wiestler OD, Louis DN, von Deimling A (2002) Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 161:313–319

    CAS  PubMed  Google Scholar 

  123. Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68:820–823

    PubMed  Google Scholar 

  124. Iuchi T, Namba H, Iwadate Y, Shishikura T, Kageyama H, Nakamura Y, Ohira M, Yamaura A, Osato K, Sakiyama S, Nakagawara A (2002) Identification of the small interstitial deletion at chromosome band 1p34–p35 and its association with poor outcome in oligodendroglial tumors. Genes Chromosomes Cancer 35:170–175

    Article  CAS  PubMed  Google Scholar 

  125. Zhu JJ, Santarius T, Wu X, Tsong J, Guha A, Wu JK, Hudson TJ, Black PM (1998) Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas. Genes Chromosomes Cancer 21:207–216

    Article  CAS  PubMed  Google Scholar 

  126. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, Hosek SM, Kimmel D, O’Fallon J, Yates A, Feuerstein BG, Burger PC, Scheithauer BW, Jenkins RB (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144–4152

    Article  CAS  PubMed  Google Scholar 

  127. Husemann K, Wolter M, Buschges R, Bostrom J, Sabel M, Reifenberger G (1999) Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. J Neuropathol Exp Neurol 58:1041–1050

    CAS  PubMed  Google Scholar 

  128. Alonso ME, Bello MJ, Gonzalez-Gomez P, Lomas J, Arjona D, de Campos JM, Kusak ME, Sarasa JL, Isla A, Rey JA (2001) Mutation analysis of the p73 gene in nonastrocytic brain tumours. Br J Cancer 85:204–208

    Article  CAS  PubMed  Google Scholar 

  129. Mai M, Huang H, Reed C, Qian C, Smith JS, Alderete B, Jenkins R, Smith DI, Liu W (1998) Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. Genomics 51:359–363

    Article  CAS  PubMed  Google Scholar 

  130. Tsujimoto T, Mochizuchi S, Iwadate Y, Namba H, Nagai M, Kawamoto T, Sunahara M, Yamaura A, Nakagawara A, Sakiyama S, Tagawa M (2000) The p73 gene is not mutated in oligodendrogliomas which frequently have a deleted region at chromosome 1p36.3. Anticancer Res 20:2495–2497

    CAS  PubMed  Google Scholar 

  131. Kroiss MM, Bosserhoff AK, Vogt T, Buettner R, Bogenrieder T, Landthaler M, Stolz W (1998) Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas. Melanoma Res 8:504–509

    CAS  PubMed  Google Scholar 

  132. Lomas J, Bello MJ, Arjona D, Gonzalez-Gomez P, Alonso ME, de Campos JM, Vaquero J, Ruiz-Barnes P, Sarasa JL, Casartelli C, Rey JA (2001) Analysis of p73 gene in meningiomas with deletion at 1p. Cancer Genet Cytogenet 129:88–91

    Article  CAS  PubMed  Google Scholar 

  133. Ichimiya S, Nimura Y, Kageyama H, Takada N, Sunahara M, Shishikura T, Nakamura Y, Sakiyama S, Seki N, Ohira M, Kaneko Y, McKeon F, Caput D, Nakagawara A (1999) p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. Oncogene 18:1061–1066

    Article  CAS  PubMed  Google Scholar 

  134. Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T (1998) Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 58:1380–1383

    CAS  PubMed  Google Scholar 

  135. Sunahara M, Ichimiya S, Nimura Y, Takada N, Sakiyama S, Sato Y, Todo S, Adachi W, Amano J, Nakagawara A (1998) Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas. Int J Oncol 13:319–323

    CAS  PubMed  Google Scholar 

  136. Shishikura T, Ichimiya S, Ozaki T, Nimura Y, Kageyama H, Nakamura Y, Sakiyama S, Miyauchi M, Yamamoto N, Suzuki M, Nakajima N, Nakagawara A (1999) Mutational analysis of the p73 gene in human breast cancers. Int J Cancer 84:321–325

    Article  CAS  PubMed  Google Scholar 

  137. Takahashi H, Ichimiya S, Nimura Y, Watanabe M, Furusato M, Wakui S, Yatani R, Aizawa S, Nakagawara A (1998) Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res 58:2076–2077

    CAS  PubMed  Google Scholar 

  138. Dong SM, Pang JC, Poon WS, Hu J, To KF, Chang AR, Ng HK (2001) Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol 60:808–816

    CAS  PubMed  Google Scholar 

  139. Dong S, Pang JC, Hu J, Zhou LF, Ng HK (2002) Transcriptional inactivation of TP73 expression in oligodendroglial tumors. Int J Cancer 98:370–375

    Article  CAS  PubMed  Google Scholar 

  140. Watanabe T, Huang H, Nakamura M, Wischhusen J, Weller M, Kleihues P, Ohgaki H (2002) Methylation of the p73 gene in gliomas. Acta Neuropathol (Berl) 104:357–362

    Google Scholar 

  141. Matsuda M, Miyagawa K, Takahashi M, Fukuda T, Kataoka T, Asahara T, Inui H, Watatani M, Yasutomi M, Kamada N, Dohi K, Kamiya K (1999) Mutations in the RAD54 recombination gene in primary cancers. Oncogene 18:3427–3430

    Article  CAS  PubMed  Google Scholar 

  142. Bello MJ, de Campos JM, Vaquero J, Ruiz-Barnes P, Kusak ME, Sarasa JL, Rey JA (2000) hRAD54 gene and 1p high-resolution deletion-mapping analyses in oligodendrogliomas. Cancer Genet Cytogenet 116:142–147

    Article  CAS  PubMed  Google Scholar 

  143. He J, Hoang-Xuan K, Marie Y, Leuraud P, Mokhtari K, Kujas M, Delattre JY, Sanson M (2000) P18 tumor suppressor gene and progression of oligodendrogliomas to anaplasia. Neurology 55:867–869

    CAS  PubMed  Google Scholar 

  144. Pohl U, Cairncross JG, Louis DN (1999) Homozygous deletions of the CDKN2C/p18INK4C gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas. Brain Pathol 9:639–643

    CAS  PubMed  Google Scholar 

  145. Rosenberg JE, Lisle DK, Burwick JA, Ueki K, von Deimling A, Mohrenweiser HW, Louis DN (1996) Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene 13:2483–2485

    CAS  PubMed  Google Scholar 

  146. Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H (2000) Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 59:539–543

    CAS  PubMed  Google Scholar 

  147. Deimling A von, Bender B, Jahnke R, Waha A, Kraus J, Albrecht S, Wellenreuther R, Fassbender F, Nagel J, Menon AG et al. (1994) Loci associated with malignant progression in astrocytomas: a candidate on chromosome 19q. Cancer Res 54:1397–1401

    PubMed  Google Scholar 

  148. Deimling A von, Nagel J, Bender B, Lenartz D, Schramm J, Louis DN, Wiestler OD (1994) Deletion mapping of chromosome 19 in human gliomas. Int J Cancer 57:676–680

    PubMed  Google Scholar 

  149. Rubio MP, Correa KM, Ueki K, Mohrenweiser HW, Gusella JF, von Deimling A, Louis DN (1994) The putative glioma tumor suppressor gene on chromosome 19q maps between APOC2 and HRC. Cancer Res 54:4760–4763

    CAS  PubMed  Google Scholar 

  150. Yong WH, Chou D, Ueki K, Harsh GRt, von Deimling A, Gusella JF, Mohrenweiser HW, Louis DN (1995) Chromosome 19q deletions in human gliomas overlap telomeric to D19S219 and may target a 425 kb region centromeric to D19S112. J Neuropathol Exp Neurol 54:622–626

    CAS  PubMed  Google Scholar 

  151. Smith JS, Tachibana I, Lee HK, Qian J, Pohl U, Mohrenweiser HW, Borell TJ, Hosek SM, Soderberg CL, von Deimling A, Perry A, Scheithauer BW, Louis DN, Jenkins RB (2000) Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes Cancer 29:16–25

    Article  CAS  PubMed  Google Scholar 

  152. Smith JS, Tachibana I, Pohl U, Lee HK, Thanarajasingam U, Portier BP, Ueki K, Ramaswamy S, Billings SJ, Mohrenweiser HW, Louis DN, Jenkins RB (2000) A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics 64:44–50

    Article  CAS  PubMed  Google Scholar 

  153. Pohl U, Smith JS, Tachibana I, Ueki K, Lee HK, Ramaswamy S, Wu Q, Mohrenweiser HW, Jenkins RB, Louis DN (2000) EHD2, EHD3, and EHD4 encode novel members of a highly conserved family of EH domain-containing proteins. Genomics 63:255–262

    Article  CAS  PubMed  Google Scholar 

  154. Hartmann C, Johnk L, Kitange G, Wu Y, Ashworth LK, Jenkins RB, Louis DN (2002) Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19. Cancer Res 62:4100–4108

    CAS  PubMed  Google Scholar 

  155. Chou D, Miyashita T, Mohrenweiser HW, Ueki K, Kastury K, Druck T, von Deimling A, Huebner K, Reed JC, Louis DN (1996) The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer Genet Cytogenet 88:136–140

    Article  CAS  PubMed  Google Scholar 

  156. Tikoo A, Czekay S, Viars C, White S, Heath JK, Arden K, Maruta H (2000) p190-A, a human tumor suppressor gene, maps to the chromosomal region 19q13.3 that is reportedly deleted in some gliomas. Gene 257:23–31

    Article  CAS  PubMed  Google Scholar 

  157. Wolf RM, Draghi N, Liang X, Dai C, Uhrbom L, Eklof C, Westermark B, Holland EC, Resh MD (2003) p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3. Genes Dev 17:476–487

    Article  CAS  PubMed  Google Scholar 

  158. Gaozza E, Baker SJ, Vora RK, Reddy EP (1997) AATYK: a novel tyrosine kinase induced during growth arrest and apoptosis of myeloid cells. Oncogene 15:3127–3135

    Article  CAS  PubMed  Google Scholar 

  159. Raghunath M, Patti R, Bannerman P, Lee CM, Baker S, Sutton LN, Phillips PC, Damodar Reddy C (2000) A novel kinase, AATYK induces and promotes neuronal differentiation in a human neuroblastoma (SH-SY5Y) cell line. Brain Res Mol Brain Res 77:151–162

    Article  CAS  PubMed  Google Scholar 

  160. Mukasa A, Ueki K, Matsumoto S, Tsutsumi S, Nishikawa R, Fujimaki T, Asai A, Kirino T, Aburatani H (2002) Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 21:3961–3968

    Article  CAS  PubMed  Google Scholar 

  161. Sanson M, Leuraud P, Marie Y, Delattre JY, Hoang-Xuan K (2002) Preferential loss of paternal 19q, but not 1p, alleles in oligodendrogliomas. Ann Neurol 52:105–107

    Article  CAS  PubMed  Google Scholar 

  162. Maegawa S, Yoshioka H, Itaba N, Kubota N, Nishihara S, Shirayoshi Y, Nanba E, Oshimura M (2001) Epigenetic silencing of PEG3 gene expression in human glioma cell lines. Mol Carcinog 31:1–9

    Article  CAS  PubMed  Google Scholar 

  163. Kohda T, Asai A, Kuroiwa Y, Kobayashi S, Aisaka K, Nagashima G, Yoshida MC, Kondo Y, Kagiyama N, Kirino T, Kaneko-Ishino T, Ishino F (2001) Tumour suppressor activity of human imprinted gene PEG3 in a glioma cell line. Genes Cells 6:237–247

    Article  CAS  PubMed  Google Scholar 

  164. Hartmann C, Mueller W, Lass U, Stockhammer F, von Eckardstein K, Veelken J, Jeuken J, Wick W, von Deimling A (2003) No preferential loss of paternal 19q alleles in oligodendroglial tumors. Ann Neurol 54:256–258

    Article  CAS  PubMed  Google Scholar 

  165. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, Wiestler OD, Louis DN, Fimmers R, von Deimling A (2002) Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61:321–328

    CAS  PubMed  Google Scholar 

  166. Kros JM, van Run PR, Alers JC, Beverloo HB, van den Bent MJ, Avezaat CJ, van Dekken H (1999) Genetic aberrations in oligodendroglial tumours: an analysis using comparative genomic hybridization (CGH). J Pathol 188:282–288

    Article  CAS  PubMed  Google Scholar 

  167. Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM, McLendon RE, Bigner DD (1999) Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 155:375–386

    CAS  PubMed  Google Scholar 

  168. Weber RG, Sabel M, Reifenberger J, Sommer C, Oberstrass J, Reifenberger G, Kiessling M, Cremer T (1996) Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Oncogene 13:983–9894

    CAS  PubMed  Google Scholar 

  169. Alonso ME, Bello MJ, Arjona D, Gonzalez-Gomez P, Lomas J, de Campos JM, Kusak ME, Isla A, Rey JA (2002) Analysis of the NF2 gene in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet 134:1–5

    Article  CAS  PubMed  Google Scholar 

  170. Weber M, Stockhammer F, Schmitz U, von Deimling A (2001) Mutational analysis of INI1 in sporadic human brain tumors. Acta Neuropathol (Berl) 101:479–482

    Google Scholar 

  171. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P (1991) p53 mutations in nonastrocytic human brain tumors. Cancer Res 51:6202–6205

    CAS  PubMed  Google Scholar 

  172. Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, Ohgaki H (2002) Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol (Berl) 103:267–275

    Google Scholar 

  173. Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N, Fujimaki T, Hojo S, Kubo O, Ide T, Usui M, Ochiai C, Ito S, Takahashi H, Mukasa A, Asai A, Kirino T (2002) Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 8:196–201

    CAS  PubMed  Google Scholar 

  174. Wolter M, Reifenberger J, Blaschke B, Ichimura K, Schmidt EE, Collins VP, Reifenberger G (2001) Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. J Neuropathol Exp Neurol 60:1170–1180

    CAS  PubMed  Google Scholar 

  175. Burger PC, Minn AY, Smith JS, Borell TJ, Jedlicka AE, Huntley BK, Goldthwaite PT, Jenkins RB, Feuerstein BG (2001) Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 14:842–853

    Article  CAS  PubMed  Google Scholar 

  176. Jeuken JW, Sprenger SH, Wesseling P, Macville MV, von Deimling A, Teepen HL, van Overbeeke JJ, Boerman RH (1999) Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol 58:606–612

    CAS  PubMed  Google Scholar 

  177. Deimling A von, Fimmers R, Schmidt MC, Bender B, Fassbender F, Nagel J, Jahnke R, Kaskel P, Duerr EM, Koopmann J, Maintz D, Steinbeck S, Wick W, Platten M, Muller DJ, Przkora R, Waha A, Blumcke B, Wellenreuther R, Meyer-Puttlitz B, Schmidt O, Mollenhauer J, Poustka A, Stangl AP, Lenartz D, von Ammon K (2000) Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 59:544–558

    PubMed  Google Scholar 

  178. Bortolotto S, Chiado-Piat L, Cavalla P, Bosone I, Chio A, Mauro A, Schiffer D (2000) CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer 88:554–557

    Article  CAS  PubMed  Google Scholar 

  179. Watanabe T, Yokoo H, Yokoo M, Yonekawa Y, Kleihues P, Ohgaki H (2001) Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol 60:1181–1189

    CAS  PubMed  Google Scholar 

  180. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501–1512

    CAS  PubMed  Google Scholar 

  181. Ruas M, Peters G (1998) The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378:F115–F177

    Article  CAS  PubMed  Google Scholar 

  182. Sherr CJ, Weber JD (2000) The ARF/p53 pathway. Curr Opin Genet Dev 10:94–99

    Article  CAS  PubMed  Google Scholar 

  183. Ohgaki H, Eibl RH, Schwab M, Reichel MB, Mariani L, Gehring M, Petersen I, Holl T, Wiestler OD, Kleihues P (1993) Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog 8:74–80

    CAS  PubMed  Google Scholar 

  184. Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, Stangl AP, Louis DN, Schramm J, Wiestler OD, von Deimling A (1997) Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 56:1098–1104

    CAS  PubMed  Google Scholar 

  185. Bissola L, Eoli M, Pollo B, Merciai BM, Silvani A, Salsano E, Maccagnano C, Bruzzone MG, Fuhrman Conti AM, Solero CL, Giombini S, Broggi G, Boiardi A, Finocchiaro G (2002) Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. Ann Neurol 52:842–845

    Article  PubMed  Google Scholar 

  186. Jeuken JW, Sprenger SH, Vermeer H, Kappelle AC, Boerman RH, Wesseling P (2002) Chromosomal imbalances in primary oligodendroglial tumors and their recurrences: clues about malignant progression detected using comparative genomic hybridization. J Neurosurg 96:559–564

    PubMed  Google Scholar 

  187. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, Schramm J, Wiestler OD, Parsons R, Eng C, von Deimling A (1998) PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16:2259–2264

    Article  CAS  PubMed  Google Scholar 

  188. Jeuken JW, Nelen MR, Vermeer H, van Staveren WC, Kremer H, van Overbeeke JJ, Boerman RH (2000) PTEN mutation analysis in two genetic subtypes of high-grade oligodendroglial tumors. PTEN is only occasionally mutated in one of the two genetic subtypes. Cancer Genet Cytogenet 119:42–47

    Article  CAS  PubMed  Google Scholar 

  189. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN (2001) PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 159:359–367

    CAS  PubMed  Google Scholar 

  190. Maier D, Comparone D, Taylor E, Zhang Z, Gratzl O, Van Meir EG, Scott RJ, Merlo A (1997) New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25–26. Oncogene 15:997–1000

    Article  CAS  PubMed  Google Scholar 

  191. Alonso ME, Bello MJ, Gonzalez-Gomez P, Arjona D, Lomas J, de Campos JM, Isla A, Sarasa JL, Rey JA (2003) Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet 144:134–142

    Article  CAS  PubMed  Google Scholar 

  192. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428

    Article  CAS  PubMed  Google Scholar 

  193. Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H (2001) Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. Acta Neuropathol (Berl) 101:185–189

    Google Scholar 

  194. Uhlmann K, Rohde K, Zeller C, Szymas J, Vogel S, Marczinek K, Thiel G, Nurnberg P, Laird PW (2003) Distinct methylation profiles of glioma subtypes. Int J Cancer 106:52–59

    Article  CAS  PubMed  Google Scholar 

  195. Hong C, Bollen AW, Costello JF (2003) The contribution of genetic and epigenetic mechanisms to gene silencing in oligodendrogliomas. Cancer Res 63:7600–7605

    CAS  PubMed  Google Scholar 

  196. Reifenberger J, Reifenberger G, Ichimura K, Schmidt EE, Wechsler W, Collins VP (1996) Epidermal growth factor receptor expression in oligodendroglial tumors. Am J Pathol 149:29–35

    CAS  PubMed  Google Scholar 

  197. Reifenberger G, Prior R, Deckert M, Wechsler W (1989) Epidermal growth factor receptor expression and growth fraction in human tumours of the nervous system. Virchows Arch A Pathol Anat Histopathol 414:147–155

    CAS  PubMed  Google Scholar 

  198. Torp SH, Helseth E, Ryan L, Stolan S, Dalen A, Unsgaard G (1991) Amplification of the epidermal growth factor receptor gene in human gliomas. Anticancer Res 11:2095–2098

    CAS  PubMed  Google Scholar 

  199. Broholm H, Bols B, Heegaard S, Braendstrup O (1999) Immunohistochemical investigation of p53 and EGFR expression of oligodendrogliomas. Clin Neuropathol 18:176–180

    CAS  PubMed  Google Scholar 

  200. Diedrich U, Soja S, Behnke J, Zoll B (1991) Amplification of the c-erbB oncogene is associated with malignancy in primary tumours of neuroepithelial tissue. J Neurol 238:221–224

    CAS  PubMed  Google Scholar 

  201. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP (1991) Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51:2164–2172

    CAS  PubMed  Google Scholar 

  202. Hawkins RA, Killen E, Whittle IR, Jack WJ, Chetty U, Prescott RJ (1991) Epidermal growth factor receptors in intracranial and breast tumours: their clinical significance. Br J Cancer 63:553–560

    CAS  PubMed  Google Scholar 

  203. McLendon RE, Wikstrand CJ, Matthews MR, Al-Baradei R, Bigner SH, Bigner DD (2000) Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. J Histochem Cytochem 48:1103–1110

    CAS  PubMed  Google Scholar 

  204. Schwechheimer K, Gass P, Berlet HH (1992) Expression of oligodendroglia and Schwann cell markers in human nervous system tumors. An immunomorphological study and western blot analysis. Acta Neuropathol (Berl) 83:283–291

    Google Scholar 

  205. Wong AJ, Zoltick PW, Moscatello DK (1994) The molecular biology and molecular genetics of astrocytic neoplasms. Semin Oncol 21:139–148

    CAS  PubMed  Google Scholar 

  206. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283–12316

    CAS  PubMed  Google Scholar 

  207. Durand B, Raff M (2000) A cell-intrinsic timer that operates during oligodendrocyte development. Bioessays 22:64–71

    Article  CAS  PubMed  Google Scholar 

  208. Calver AR, Hall AC, Yu WP, Walsh FS, Heath JK, Betsholtz C, Richardson WD (1998) Oligodendrocyte population dynamics and the role of PDGF in vivo. Neuron 20:869–882

    Article  CAS  PubMed  Google Scholar 

  209. Yeh HJ, Ruit KG, Wang YX, Parks WC, Snider WD, Deuel TF (1991) PDGF A-chain gene is expressed by mammalian neurons during development and in maturity. Cell 64:209–216

    Article  CAS  PubMed  Google Scholar 

  210. Robinson S, Cohen M, Prayson R, Ransohoff RM, Tabrizi N, Miller RH (2001) Constitutive expression of growth-related oncogene and its receptor in oligodendrogliomas. Neurosurgery 48:864–873–

    CAS  PubMed  Google Scholar 

  211. Di Rocco F, Carroll RS, Zhang J, Black PM (1998) Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery 42:341–346

    Article  PubMed  Google Scholar 

  212. Maxwell M, Naber SP, Wolfe HJ, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniades HN (1990) Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J Clin Invest 86:131–140

    CAS  PubMed  Google Scholar 

  213. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, Nister M (1992) Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52:3213–3219

    CAS  PubMed  Google Scholar 

  214. Hermanson M, Funa K, Koopmann J, Maintz D, Waha A, Westermark B, Heldin CH, Wiestler OD, Louis DN, von Deimling A, Nister M (1996) Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res 56:164–171

    CAS  PubMed  Google Scholar 

  215. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU (1992) Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52:4550–4553

    CAS  PubMed  Google Scholar 

  216. Smith JS, Wang XY, Qian J, Hosek SM, Scheithauer BW, Jenkins RB, James CD (2000) Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol 59:495–503

    CAS  PubMed  Google Scholar 

  217. Uhrbom L, Hesselager G, Nister M, Westermark B (1998) Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 58:5275–5279

    CAS  PubMed  Google Scholar 

  218. Uhrbom L, Hesselager G, Ostman A, Nister M, Westermark B (2000) Dependence of autocrine growth factor stimulation in platelet-derived growth factor-B-induced mouse brain tumor cells. Int J Cancer 85:398–406

    Article  CAS  PubMed  Google Scholar 

  219. McKinnon RD, Smith C, Behar T, Smith T, Dubois-Dalcq M (1993) Distinct effects of bFGF and PDGF on oligodendrocyte progenitor cells. Glia 7:245–254

    CAS  PubMed  Google Scholar 

  220. McKinnon RD, Piras G, Ida JA Jr, Dubois-Dalcq M (1993) A role for TGF-beta in oligodendrocyte differentiation. J Cell Biol 121:1397–1407

    Article  CAS  PubMed  Google Scholar 

  221. McMorris FA, Mozell RL, Carson MJ, Shinar Y, Meyer RD, Marchetti N (1993) Regulation of oligodendrocyte development and central nervous system myelination by insulin-like growth factors. Ann N Y Acad Sci 692:321–334

    CAS  PubMed  Google Scholar 

  222. Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus JA, Schlegel U, Reifenberger G (1999) Amplification and overexpression of the MDM 4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM 2 amplification. Cancer Res 59:6091–6096

    CAS  PubMed  Google Scholar 

  223. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WO, Weinstein JN, Mesirov JP, Lander ES, Golub TR (2001) Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 98:10787–10792

    Article  CAS  PubMed  Google Scholar 

  224. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, Ladd C, Reich M, Latulippe E, Mesirov JP, Poggio T, Gerald W, Loda M, Lander ES, Golub TR (2001) Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 98:15149–15154

    Article  CAS  PubMed  Google Scholar 

  225. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531–537

    Article  CAS  PubMed  Google Scholar 

  226. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ, Meyerson M (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 98:13790–13795

    Article  CAS  PubMed  Google Scholar 

  227. Russo G, Zegar C, Giordano A (2003) Advantages and limitations of microarray technology in human cancer. Oncogene 22:6497–6507

    Article  CAS  PubMed  Google Scholar 

  228. Fuller GN, Hess KR, Rhee CH, Yung WK, Sawaya RA, Bruner JM, Zhang W (2002) Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol 12:108–116

    CAS  PubMed  Google Scholar 

  229. Kim S, Dougherty ER, Shmulevich L, Hess KR, Hamilton SR, Trent JM, Fuller GN, Zhang W (2002) Identification of combination gene sets for glioma classification. Mol Cancer Ther 1:1229–1236

    CAS  PubMed  Google Scholar 

  230. Watson MA, Perry A, Budhjara V, Hicks C, Shannon WD, Rich KM (2001) Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res 61:1825–1829

    CAS  PubMed  Google Scholar 

  231. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN (2003) Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63:1602–1607

    CAS  PubMed  Google Scholar 

  232. Mora J, Cheung NK, Chen L, Qin J, Gerald W (2001) Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clin Cancer Res 7:1358–1361

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuropathology, Charité Hospital, Berlin, Germany

    Christian Hartmann, Wolf Mueller & Andreas von Deimling

Authors
  1. Christian Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolf Mueller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andreas von Deimling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Hartmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hartmann, C., Mueller, W. & von Deimling, A. Pathology and molecular genetics of oligodendroglial tumors. J Mol Med 82, 638–655 (2004). https://doi.org/10.1007/s00109-004-0565-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00109-004-0565-9

Keywords

Search

Navigation